# PMGC Holdings Inc. (ELAB)

> Source: Nexqual · https://nexqual.com/ELAB · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, PMGC Holdings Inc. (ELAB), nexqual.com/ELAB" · informational, not investment advice.

**Price:** USD 2.71 (+0.52% on the day) · last close of Oct 23, 2026; US market after hours, not a live price. Prev close 2.69 · day 2.71–2.76 · 52w 2.59–1,537.44 · market cap $2.2M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $2.6M, net income -$13.5M (-523.0% margin) (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -99.8% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $766K | $1.7M | — | $590K | $2.6M |
| Gross profit | $447K | $1.1M | — | $185K | — |
| Net income | -$1.8M | -$4.3M | -$6.2M | -$7.7M | -$13.5M |
| EPS (diluted) | -$222821.05 | -$471578.95 | — | — | — |
| Free cash flow | — | -$4.6M | -$5.5M | -$6.4M | — |
| Gross margin | 58.4% | 66.2% | — | 31.4% | — |
| Net margin | -234.9% | -251.2% | — | -1313.0% | -523.0% |
| Revenue growth | — | +123.5% | — | — | — |
| Cash + short-term investments | $1.2M | $3.3M | $4.0M | $6.0M | — |
| Total debt | — | — | — | $85K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.8x · P/B 0.1x · Earnings yield -615.65%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2023-11-20) |
|---|---|---|
| Total return | -99.8% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -99.8% | -99.2% |
| Volatility (annualized) | 213.4% | 176.8% |
| Max drawdown | -99.8% (Oct 2025→Oct 2026) | -100.0% (Nov 2023→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/ELAB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ELAB's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1840563/000121390026035937/ea0282650-10k_pmgc.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | AGA Precision Systems | "we are unable to expand AGA's customer base beyond its existing network of relationships, AGA's growth may be limited and" |
| Partner | Company and MOA Life Plus | "If MOA terminates the License Agreement under the terms thereunder, including, amongst other things, if we breach our" |

## Customer concentration

Period ended 2026-06-30: 11.9%, 11.9% of revenue from unnamed direct customers (10-Q, filed 2026-08-14).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |